1.03

5.50% -0.06

Allarity Therapeutics Inc (ALLR)

Overview News Price History Financials Discussions Forecast Stock Split

Allarity Therapeutics Inc stock is traded at $1.03, with a volume of 43,254. It is down -5.50% in the last 24 hours and down -22.56% over the past month. Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.

Previous Close:

$1.09

Open:

$1.09

24h Volume:

43,254

Relative Volume:

0.44

Market Cap:

$16.39M

Revenue:

$345.00K

Net Income/Loss:

$-11.25M

P/E Ratio:

-1.4272

EPS:

-0.7217

Net Cash Flow:

$-16.70M

1W Performance:

-14.88%

1M Performance:

-22.56%

6M Performance:

-8.04%

1Y Performance:

-33.12%

1-Day Range:

$1.03

$1.10

1-Week Range:

$1.01

$1.23

52-Week Range:

$0.7687

$1.8395

Allarity Therapeutics Inc Stock (ALLR) Company Profile

Name

Allarity Therapeutics Inc

Sector

Healthcare (1067)

Industry

Biotechnology (595)

Phone

401-426-4664

Address

24 SCHOOL ST., 2ND FLOOR, BOSTON

Employee

Twitter

Next Earnings Date

2026-11-13

Latest SEC Filings

ALLR's Discussions on Twitter

Compare ALLR vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALLR Allarity Therapeutics Inc	1.03	16.39M	345.00K	-11.25M	-16.70M	-0.7217
VRTX Vertex Pharmaceuticals Inc	526.19	133.37B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	788.04	81.13B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	198.88	79.40B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	959.49	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	204.97	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Allarity Therapeutics Inc Stock (ALLR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-28-25	Initiated	Ascendiant Capital Markets	Buy

Allarity Therapeutics Inc Stock (ALLR) Latest News

Sep 21, 2026

ALLR - Finviz

Sep 21, 2026

Sep 17, 2026

Form 8K Allarity Therapeutics Inc For: 17 September By Investing.com - Investing.com India

Sep 17, 2026

Sep 16, 2026

Allarity Therapeutics Is Maintained at Buy by Ascendiant Capital - Moomoo

Sep 16, 2026

Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga

Sep 16, 2026

Ascendiant Capital maintains Buy rating on Allarity Therapeutics, $11 price target - TradingView

Sep 16, 2026

Sep 15, 2026

A cancer test to find patients likely to benefit gets a Japan patent - stocktitan.net

Sep 15, 2026

Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development - Investing News Network

Sep 15, 2026

Sep 14, 2026

Form 8K Allarity Therapeutics Inc For: 14 September By Investing.com - Investing.com India

Sep 14, 2026

Allarity Therapeutics-backed SPAC files S-1 for $100M IPO; sponsor to hold ~25% - TradingView

Sep 14, 2026

Sep 11, 2026

Allarity Therapeutics files for $100 million SPAC offering By Investing.com - Investing.com Australia

Sep 11, 2026